乳腺癌新辅助化疗疗效及其超声BI-RADS征象

  目的  分析乳腺癌患者新辅助化疗疗效与超声乳腺图像报告和数据系统(BI-RADS)征象的关系。  方法  选择我院2019年6月~2020年12月收治的86例符合标准的乳腺癌患者，根据疗效将其分为无效组(n=23)及有效组(n=63)。所有患者均采用标准新辅助化疗方案治疗；对患者行超声检查，采用BI-RADS方法记录、评估病灶危险程度。  结果  治疗后有效组患者肿瘤体积和肿瘤面积均明显低于无效组(P < 0.05)；治疗后有效组患者后方回声增强、弹性评分低和边缘清晰患者占比均明显高于无效组(P < 0.05)；治疗后两组患者BI-RADS分级明显优于治疗前(P < 0.05)，治疗后有效组患者BI-RADS分级均明显优于无效组(P < 0.05)。  结论  采用超声BI-RADS征象分析可有效提高乳腺癌患者新辅助化疗疗效的评估价值。 

Efficacy of neoadjuvant chemotherapy in breast cancer patients and its ultrasonographic BI-RADS characteristics

  Objective  To analyze the relationship between the efficacy of neoadjuvant chemotherapy and ultrasound breast image reporting and the BI-RADS signs in breast cancer patients.  Methods  Eighty-six patients who admitted to our hospital between June 2019 and December 2020 were selected and divided into ineffective group (n=23) and effective group (n=63) according to their efficacy. All patients were treated with standard neoadjuvant chemotherapy regimens. The patients were examined by ultrasonography, and the risk level of lesions was recorded and assessed using BI-RADS method.  Results  After treatment, the tumor volume and tumor area of patients in the effective group were significantly lower than those in the ineffective group (P < 0.05). The proportion of patients with clear edge, low elastic score and posterior echo enhancement in the effective group was significantly higher than that in the ineffective group (P < 0.05). The BI-RADS grading of patients in both groups was significantly better than that before treatment (P < 0.05), and the BI-RADS grading of patients in the effective group was significantly better than that of the ineffective group (P < 0.05).  Conclusion  ultrasound BI- RADS sign analysis can effectively improve the evaluation of the efficacy neoadjuvant chemotherapy in breast cancer patients.